Nurix Therapeutics, Inc. (NRIX) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
NRIX Revenue Growth
Revenue Breakdown (FY 2025)
NRIX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
NRIX Revenue Analysis (2018–2025)
As of May 8, 2026, Nurix Therapeutics, Inc. (NRIX) generated trailing twelve-month (TTM) revenue of $84.0 million, reflecting modest growth of +2.2% year-over-year. The most recent quarter (Q4 2025) recorded $13.6 million in revenue, up 72.0% sequentially.
Looking at the longer-term picture, NRIX's 5-year compound annual growth rate (CAGR) stands at +36.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $84.0 million in 2025, representing a new all-time high.
Revenue diversification analysis shows NRIX's business is primarily driven by Collaboration Revenue (64%), and License Revenue (36%). With over half of revenue concentrated in Collaboration Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ARVN (-0.3% YoY), KYMR (-12.6% YoY), and BEAM (+108.0% YoY), NRIX has underperformed the peer group in terms of revenue growth. Compare NRIX vs ARVN →
NRIX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NRIXCurrent | $84M | +2.2% | +36.3% | -340.2% | |
 ARVN | $263M | -0.3% | +58.9% | -43.8% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% |
NRIX Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $84.0M | +54.0% | $65.1M | 77.5% | $-285,666,000 | -340.2% |
| 2024 | $54.5M | -29.1% | $-167,083,000 | -306.3% | $-213,027,000 | -390.5% |
| 2023 | $77.0M | +99.3% | $-112,161,000 | -145.7% | $-155,063,000 | -201.4% |
| 2022 | $38.6M | +29.8% | $-145,870,000 | -377.6% | $-183,867,000 | -476.0% |
| 2021 | $29.8M | +66.9% | $-86,684,000 | -291.4% | $-117,886,000 | -396.3% |
| 2020 | $17.8M | -42.7% | $-48,674,000 | -273.1% | $-64,983,000 | -364.7% |
| 2019 | $31.1M | -16.9% | $-13,910,000 | -44.7% | $-22,236,000 | -71.5% |
| 2018 | $37.4M | - | $-3,065,000 | -8.2% | $-9,739,000 | -26.0% |
See NRIX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NRIX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NRIX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNRIX — Frequently Asked Questions
Quick answers to the most common questions about buying NRIX stock.
Is NRIX's revenue growth accelerating or slowing?
NRIX revenue growth slowed to +2.2%, below the 5-year CAGR of +36.3%. TTM revenue is $84M. The deceleration marks a shift from historical growth rates.
What is NRIX's long-term revenue growth rate?
Nurix Therapeutics, Inc.'s 5-year revenue CAGR of +36.3% reflects the variable expansion pattern. Current YoY growth of +2.2% is near this long-term average.
How is NRIX's revenue distributed by segment?
NRIX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.